19:30 - 9.06.2026
June 9, Fineko/abc.az. AstraZeneca's CAMBRIA-1 trial, evaluating the drug camizestrant, is being viewed as a critical short-term growth catalyst, prompting BofA Securities to maintain its "Buy" rating on the company's shares.
ABC.AZ reports that analysts have highlighted two primary advantages of the CAMBRIA-1 study over the SERENA-4 trial: a patient cohort better suited in terms of hormone therapy sensitivity, and the deployment of monotherapy, which could potentially enhance the drug's overall efficacy.
While the trial is officially scheduled for completion in April 2027, interim data readouts are anticipated to emerge much earlier.
